The Global Dry Powder Inhaler Market is expected to grow at a 4.6% CAGR from 2021 to 2031, with a market value of around US$ 18.9 billion in 2021. According to Future Market Insights, Manually Operated Inhaler Devices will account for more than 70.9% of the global dry powder inhaler market in 2021.
Request a sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-5150
Challenges Regarding Varying Characteristics of Dry Powder Inhalers to Pave Opportunities for Medical Device Manufacturers
Regulatory pressures and changes in the drug delivery market have pushed dry powder inhaler innovation forward.
According to the World Health Organization (WHO), asthma affects nearly 300 million people worldwide, and chronic obstructive pulmonary disease affects approximately 240 million (COPD).
More than half of these patients prefer to treat their disease with dry powder inhalers.
These devices have shown great promise in terms of effective and dependable drug delivery, with novel designs ensuring the ability to overcome future compliance, cost, and safety challenges.
Some of the most important performance characteristics of dry powder inhalers are dose-delivery, performance at different airflows, and fine particle fraction content.
These characteristics may differ between powder formulations, necessitating fine tuning of the device or powder formulation, or both, to achieve optimal performance.
The requirement is especially stringent in micro-dosing dry powder inhalers, which opens up opportunities for medical device manufacturers in terms of innovation and advancement.
Growing geriatric population, increasing geriatric population, and rising air pollution levels fueling the prevalence of various respiratory disorders are key factors driving the global dry powder inhaler market.
Furthermore, favourable government initiatives being implemented around the world to improve healthcare infrastructure will have a positive impact on market growth in the near future.
To Avail Discount on Report, Click@ https://www.futuremarketinsights.com/request-discount/rep-gb-5150
However, the fact that dry powder inhalers are not moisture-resistant remains a major challenge for manufacturers, as the medicine loses its properties when it comes in contact with the moisture.
Availability of effective alternatives such as nebulizers and electric pumps are expected to restrain adoption of dry powder inhalers.
Lack of awareness regarding these devices in low-income & underdeveloped countries may further hinder the market growth to a certain extent.
Key Research Findings from FMI’s Report on Dry Powder Inhaler Market
- North America will continue to be the most lucrative region for growth of the dry powder inhaler market. Dry powder inhaler sales in the region will register the fastest expansion through 2031. Asia-Pacific excluding Japan (APEJ) is expected to be the second largest market for dry powder inhaler.
- Hospital pharmacies will continue to be the leading distribution channel for dry powder inhalers, with sales pegged to surpass 150,000 Mn units by 2031-end.
- Dry powder inhalers will continue to observe the largest application in the treatment of asthma, followed by chronic obstructive pulmonary disease. In addition, sales of dry powder inhalers for application in the treatment of asthma and pulmonary arterial hypertension are slated to exhibit a parallel growth through 2031.
Leading companies in the global dry powder inhaler market are focusing on the development of new generation products.
These market players are making huge investments in R&D activities associated with novel device architectures, particle engineering, and powder formulations.
Development of improved particle properties, along with efficient inhaler designs is expected to remain key strategies among the market players. Key market participants profiled in the report include Vectura Group Plc, MannKind Corporation, Chiesi Farmaceutici S.p.A., Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Limited, Cipla Ltd., Novartis AG, GlaxoSmithKline Plc, 3M Company, and Astrazeneca Plc.
Ask For Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-5150
Key Market Segments Covered In Dry Powder Inhalers Industry Research
By Product:
- Single Dose Dry Powder Inhalers
- Multi Dose Dry Powder Inhalers
By Indication:
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Pulmonary Arterial Hypertension
- Diabetes
- Cystic Fibrosis
By Function:
- Manually Operated Inhaler Devices
- Digitally Operated Inhaler Devices
By End User:
- Institutional Sales
- Hospital Pharmacies
- Cancer Research
- Office based Speciality Clinics
- Retail Sales
- Retail Pharmacies
- Drug Stores
- Mail Order Pharmacies
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs